Almac invests in biocatalysis lauding cost and environmental benefits

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Almac invests $4m in biocatalysis R&D, describing such technologies as the way forward for the cost efficient production of highly chiral APIs and intermediates.

Outsourcing-pharma spoke with Tom Moody, head of Almac’s biocatalysis unit, who explained that the move is part of focus on bringing green manufacturing technologies to the active pharmaceutical ingredient (API) production process.

The investment, Moody continued, will increase Almac’s suite of enzyme panels, process fermentation capabilities as well as its ability to scale up these technologies for its customers.

He also predicted that Almac’s broad service portfolio of chemistry services and API manufacturing will, when combined with the expanded offering, help the firm compete in the increasingly competitive biocatalysis sector.

Related topics: Contract Manufacturing, Bulk ingredients

Related news

Show more

Related suppliers